Home
Approach
Product
About
News
Contact
News
Login
Altis in the
news
.
Follow our journey to improving patient outcomes.
Filter
All
Announcements
Publications
Media Coverage
Altis Labs announces US $6 Million in seed funding to advance AI platform for clinical trials
Altis Labs announces US $6 Million in seed funding to advance AI platform for clinical trials
Altis Labs leads $6 million pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning
Altis Labs leads $6 million pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning
Automated imaging-based prognostication (IPRO) for stage I non-small cell lung cancer using deep learning applied to computed tomography (CT) scans.
Automated imaging-based prognostication (IPRO) for stage I non-small cell lung cancer using deep learning applied to computed tomography (CT) scans.
Journal of Clinical Oncology: IPRO demonstrates accurate, automated prognostication from pretreatment CT scans of 1,110 lung cancer patients.
Journal of Clinical Oncology: IPRO demonstrates accurate, automated prognostication from pretreatment CT scans of 1,110 lung cancer patients.
ASCO: Automated imaging-based stratification of early-stage lung cancer patients using deep learning applied to pretreatment CT scans
ASCO: Automated imaging-based stratification of early-stage lung cancer patients using deep learning applied to pretreatment CT scans
ASCO: Deep learning applied to pretreatment CTs provides personalized prognostic insight for lung cancer patients
ASCO: Deep learning applied to pretreatment CTs provides personalized prognostic insight for lung cancer patients
Previous
Altis Labs Launches Digital Twins for Clinical Trials with Global Biopharmaceuticals & Leading Research Institutions
Altis Labs announces US $6 Million in seed funding to advance AI platform for clinical trials
Altis Labs leads $6 million pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning
ESMO: Evaluation of Imaging-Based Prognostication (IPRO) for Advanced Non-Small Cell Lung Cancer Using Deep Learning Applied to CT Scans
ESMO: AI-Based Prognostication from Baseline CT Scans in a Phase 3 Advanced Non-Small Cell Lung Cancer Trial
Automated imaging-based prognostication (IPRO) for stage I non-small cell lung cancer using deep learning applied to computed tomography (CT) scans.
Journal of Clinical Oncology: IPRO demonstrates accurate, automated prognostication from pretreatment CT scans of 1,110 lung cancer patients.
ASCO: Automated imaging-based stratification of early-stage lung cancer patients using deep learning applied to pretreatment CT scans
ASCO: Deep learning applied to pretreatment CTs provides personalized prognostic insight for lung cancer patients
Inside Precision Medicine: How Is Artificial Intelligence Changing the Clinical Trials Landscape?
STAT News: As AI proliferates, biopharma companies seek to harness it in clinical trials
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
Fierce Biotech: Altis Labs reels in $6M in seed funding for AI imaging used in clinical trials
Axios: Clinical trial startup seeds $6M to speed research
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI
.png)
.png)
.png)
